Effect of Tirellizumab Combined with Antirotinib on Serum Tumor Mark-ers in the Treatment of Advanced Lung Adenocarcinoma
Objective To analyze the clinical efficacy of tirellizumab combined with antirotinib in the treatment of ad-vanced lung adenocarcinoma.Methods Clinical data of 120 patients with advanced lung adenocarcinoma treated in Jinjiang City Hospital from January 2021 to December 2022 were retrospectively selected,and the patients were di-vided into study group and control group according to different therapeutic drugs,with 60 cases in each group.The control group was treated with antirotinib hydrochloride capsule,and the study group was treated with tirellizumab in-jection on the basis of the control group.Clinical efficacy,carcinoembryonic(CEA),neuronspecific(NSE),cytokeratin antigen 21-1(CYFRA21-1)level and incidence of adverse reactions were compared between the two groups.Results The effective rate of the study group was higher than that of the control group,and the difference was statistically sig-nificant(P<0.05).After treatment,CEA,NSE and CYFRA21-1 levels in the study group were(7.26±0.63),(15.62±4.28)and(10.68±2.07)ng/mL,respectively,lower than those in the control group,and the differences were statisti-cally significant(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Tirellizumab combined with antirotinib has significant efficacy in patients with advanced lung adenocarcinoma.They can improve the therapeutic effect of lung adenocarcinoma and reduce the level of tumor markers,and will not increase the risk of adverse reactions,and has high safety,which can improve the survival time and quality of life of patients.
NETL
NSTL
万方数据
维普
